psychiatryПСИХИАТРИЯPsychiatry (Moscow) (Psikhiatriya)1683-83192618-6667FSBSI “The Mental Health Research Centre”; LLC «Publisher «MIA»2618-6667-2018-77-123-133psychiatry-323Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWSМеханизмы действия, клинические аспекты и побочные эффекты антидепрессантов группы СИОЗСThe SSRI antidepressants: clinical aspects, new side effects and mechanisms of actionsВербенкоВиктория АнатольевнаVerbenkoVictoria

профессор

PhD, MD, professor

psytavr@mail.ruДвирскийАлександр АнатольевичDvirskyAlexandre

профессор

PhD, MD, professor

advir@mail.ruМедицинская академия имени С.И. Георгиевского, ФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского», СимферопольРоссияMedical Academy named after S.I. Georgievsky of Vernadsky CFU, SimferopolRussian Federation201831102018177123133Copyright © Вербенко В.А., Двирский А.А., 20182018Вербенко В.А., Двирский А.А.Verbenko V., Dvirsky A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.journalpsychiatry.com/jour/article/view/323

Цель: рассмотреть логические связи между нейробиологическими моделями, экспериментальными данными и клиническим применением СИОЗС при лечении тревожных и депрессивных расстройств. Метод: систематический обзор. Результаты: достижения экспериментальной нейробиологии являются основанием интерпретации различных вариантов поведения, ассоциированных с тревожными и депрессивными расстройствами. Особое внимание уделено нейробиологическим основам клинических и побочных эффектов антидепрессантов группы селективных ингибиторов обратного захвата серотонина (СИОЗС). Описаны кинические инструменты, которые бы позволили использовать рецепторные профили препаратов группы СИОЗС и данные доказательной медицины при назначении терапии. Вывод: приведенные данные могут служить рекомендациями для использования врачами в рутинной практике.

The aim was to create a logical connection between neurobiological models, experimental data and the clinical use of SSRIs to the treatment of anxiety and depressive disorders. Method: a systematic review and an analyzis of scientifc publications. Results: data of clinical investigations give a presentation on mechanisms of action, clinical aspects and side effects of SSRI antidepressants. Attention has been paid to the interpretation of the various behaviors, associated with these disorders through the prism of experimental neurobiology. Particular attention is paid to the neurobiological basis of the clinical and side effects of serotonin reuptake group antidepressants. There are background recommendations to use receptor profles of SSRIs for good clinical therapeutic results. Conclusion: this knowledge would be used in routine clinical practice.

психофармакотерапияантидепрессантыСИОЗСнейромедиаторные системыпобочные явленияpsychopharmacotherapyantidepressantsSSRIneurotransmitter systemsside effectsadverse eventsReferencesJacob B.L., Azmita E.C. Structure and function of the brain serotonin system. Physiology Review. 1992;72(1):165–229. doi: 10.1152/ physrev.1992.72.1.165Jacob B.L., Azmita E.C. Structure and function of the brain serotonin system. Physiology Review. 1992; 72(1):165–229. doi: 10.1152/ physrev.1992.72.1.165Chinta S.J., Andersen J.K. Dopaminergic neurons. J. Biochem. Cell Biol. 2005;7(5):942–946. doi: 10.1016/j.biocel.2004.09.009Chinta S.J., Andersen J.K. Dopaminergic neurons. J. Biochem. Cell Biol. 2005;7(5):942–946. doi: 10.1016/j.biocel.2004.09.009Martin P., Lemonnier F. The role of type 2 serotonin receptors, 5-HT2A and 5-HT2C, in depressive disorders: effect of medifoxamine. Encephale. 1994;7–8,20(4):427–435. PMID:7988407Martin P., Lemonnier F. The role of type 2 serotonin receptors, 5-HT2A and 5-HT2C, in depressive disorders: effect of medifoxamine. Encephale.1994;7–8,20(4):427–435. PMID:7988407Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O’Laughlin I.A., Meltzer H.Y. 5-HT2A and D-2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 2001;76:1521–1531. PMID:11238736Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O’Laughlin I.A., Meltzer H.Y. 5-HT2A and D-2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 2001;76:1521–1531. PMID:11238736Halberstadt A.L., Sindhunata I.S., Scheffers K., Flynn A.D., Sharp R.F., Geyer M.A., Young J.W. Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice. Neuropharmacology. 2016;107(8):364–375. doi: 10.1016/j.Halberstadt A.L., Sindhunata I.S., Scheffers K., Flynn A.D., Sharp R.F., Geyer M.A., Young J.W. Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice. Neuropharmacology. 2016;107(8):364–375. doi: 10.1016/j.Porras G., Di Matteo V., Fracasso C., Lucas G., De Deurwaerdère P., Caccia S., Esposito E., Spampinato U. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology. 2002;26(3):311–324. doi: 10.1016/S0893-133X(01)00333-5Porras G., Di Matteo V., Fracasso C., Lucas G., De Deurwaerdère P., Caccia S., Esposito E., Spampinato U. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology. 2002;26(3):311–324. doi: 10.1016/S0893-133X(01)00333-5Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol. Sci. 1993;14:262. PMID:8212321Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol. Sci. 1993;14:262. PMID:8212321Owens M., Knight D., Nemeroff C. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry. 2001;50:345–350. PMID:11543737Owens M., Knight D., Nemeroff C. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry. 2001;50:345–350. PMID:11543737Celada P., Puig V., Amargós-Bosch M., Adell A., Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J. Psychiatry Neurosci. 2004;29(4):252–265. PMID:15309042Celada P., Puig V., Amargós-Bosch M., Adell A., Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J. Psychiatry Neurosci. 2004;29(4):252–265. PMID:15309042Gundlah C., Pecins-Thompson M., Schutzer W.E., Bethea C.L. Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Mol. Brain. Res. 1999;63:325–339. doi: 10.1016/ S0169-328X(98)00295-2Gundlah C., Pecins-Thompson M., Schutzer W.E., Bethea C.L. Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Mol. Brain. Res. 1999;63:325–339. doi: 10.1016/ S0169-328X(98)00295-2Tanaka E., North R.A. Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J. Neurophysiol. 1993;69:1749–1757. doi: 10.1101/lm.60803Tanaka E., North R.A. Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J. Neurophysiol. 1993;69:1749–1757. doi: 10.1101/lm.60803Lindquist K.A., Wager T.D., Kober H. The brain basis of emotion: a meta-analytic review. Behav. Brain Sci. 2012;35(3):121–143. doi: 10.1017/S0140525X11000446Lindquist K.A., Wager T.D., Kober H. The brain basis of emotion: a meta-analytic review. Behav. Brain Sci. 2012;35(3):121–143. doi: 10.1017/S0140525X11000446Araneda R., Andrade R. 5-Hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience. 1991;40:399–412. PMID:1851255Araneda R., Andrade R. 5-Hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience. 1991;40:399–412. PMID:1851255Rasanen P., Hakko H., Tiihonen J. Pindolol and major affective disorders: a three-year follow-up study of 30 485 patients. J. Clin. Psychopharmacol. 1999;19:297–302. PMID:10440455Rasanen P., Hakko H., Tiihonen J. Pindolol and major affective disorders: a three-year follow-up study of 30 485 patients. J. Clin. Psy- chopharmacol. 1999;19:297–302. PMID:10440455Hansen R.A., Gartlehner G., Lohr K.N. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann. Intern. Med. 2005;143(6):415–426. PMID:16172440Hansen R.A., Gartlehner G., Lohr K.N. Efficacy and safety of second-generation antidepressants in the treatment of major depres-sive disorder. Ann. Intern. Med. 2005;143(6):415–426. PMID:16172440Mayo Clinic Staff. Antidepressants: Get tips to cope with side effects. Mayo Clinic Articles. 2016. 238 p.Mayo Clinic Staff. Antidepressants: Get tips to cope with side effects. Mayo Clinic Articles. 2016. 238 p.Gareth J.S., Eamonn M.M. Quigley, constipation, IBS and the 5-HT4 receptor: What role for prucalopride? Clinical Medicine Insights. Gastroenterology. 2010;3:21–33. doi: 10.4137/CGast.S4136Gareth J.S., Eamonn M.M. Quigley, constipation, IBS and the 5-HT4 receptor: What role for prucalopride? Clinical Medicine Insights. Gastroenterology. 2010;3:21–33. doi: 10.4137/CGast.S4136Serretti A., Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J. Clin. Psychopharmacol. 2009;29(3):259–266. doi: 10.1097/JCP.0b013e3181a5233f.Serretti A., Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J. Clin. Psychopharmacol. 2009;29(3):259–266. doi: 10.1097/JCP.0b013e3181a5233f.Kyoung-Uk L., Young Min L., Ji-Min N., Hae-Kook L., Yong-Sil K., Chung T.L., Tae-Youn J. Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting. Psychiatry Investig. 2010;7(1):55–59. doi: 10.4306/pi.2010.7.1.55Kyoung-Uk L., Young Min L., Ji-Min N., Hae-Kook L., Yong-Sil K., Chung T.L., Tae-Youn J. Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting. Psychiatry Investig. 2010;7(1):55–59. doi: 10.4306/pi.2010.7.1.55Clayton A.H., Pradko J.F., Croft H.A., Montano C.B., Leadbetter R.A., Bolden-Watson C., Bass K.I., Donahue R.M., Jamerson B.D., Metz A. Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psychiatry. 2002;63(4):357–366. PMID:12000211Clayton A.H., Pradko J.F., Croft H.A., Montano C.B., Leadbetter R.A., Bolden-Watson C., Bass K.I., Donahue R.M., Jamerson B.D., Metz A. Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psychiatry. 2002;63(4):357–366. PMID:12000211Herrera-Guzmán I., Herrera-Abarca J.E., Gudayol-Ferré E. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res. 2010;177(3):323–329. doi: 10.1016/j.psychres.2010.03.006Herrera-Guzmán I., Herrera-Abarca J.E., Gudayol-Ferré E. Effects of selective serotonin reuptake and dual serotonergic-norad- renergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res. 2010;177(3):323–329. doi: 10.1016/j.psychres.2010.03.006Guay D. Hyponatremia associated with selective serotonin reuptake inhibitors: clinical review. Consult. Pharmacist. 2000;15:160–177.Guay D. Hyponatremia associated with selective serotonin reuptake inhibitors: clinical review. Consult. Pharmacist. 2000;15:160–177.Dalton S.O., Johansen C., Mellemkjaer L., Nørgård B., Sørensen H.T., Olsen J.H. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch. Intern. Med. 2003;163:59–64. PMID:12523917Dalton S.O., Johansen C., Mellemkjaer L., Nørgård B., Sørensen H.T., Olsen J.H. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch. Intern. Med. 2003;163:59–64. PMID:12523917Yuan Y., Tsoi K., Hunt R.H. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am. J. Med. 2006;119:719–727. doi: 10.1016/j.amjmed.2005.11.006Yuan Y., Tsoi K., Hunt R.H. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am. J. Med. 2006;119:719–727. doi: 10.1016/j.amjmed.2005.11.006Montgomery S.A. Antidepressants and seizures: emphasis on newer agents and clinical implications. International Journal of Clinical Practice. 2005;59(12):1435–1440. doi: 10.1111/j.1368-5031.2005.00731.xMontgomery S.A. Antidepressants and seizures: emphasis on newer agents and clinical implications. International Journal of Clinical Practice. 2005;59(12):1435–1440. doi: 10.1111/j.1368-5031.2005.00731.xSkowron D.M., Stimmel G.L. Antidepressants and the risk of seizures. Pharmacotherapy. 1992;12(1):18–22. PMID:1549533Skowron D.M., Stimmel G.L. Antidepressants and the risk of sei- zures. Pharmacotherapy. 1992;12(1):18–22. PMID:1549533Hill T., Coupland C., Morriss R., Arthur A., Moore M., Hippisley-Cox J. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. BMC Psychiatry. 2015;15:315. doi: 10.1186/s12888-015-0701Hill T., Coupland C., Morriss R., Arthur A., Moore M., Hippisley-Cox J. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. BMC Psychiatry. 2015;15:315. doi: 10.1186/s12888-015-0701Maguire M.J., Weston J., Singh J., Marson A.G. Antidepressants for people with epilepsy and depression. Cochrane Database Syst. Rev. 2014;3(12): doi: 10.1002/14651858. CD010682.pub2.Maguire M.J., Weston J., Singh J., Marson A.G. Antidepressants for people with epilepsy and depression. Cochrane Database Syst. Rev. 2014;3(12): doi: 10.1002/14651858. CD010682.pub2.He M., Deng C., Huang X.F. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain CNS Drugs. 2013;27(6):423–434. doi: 10.1007/s40263-013-0062-1He M., Deng C., Huang X.F. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain CNS Drugs. 2013;27(6):423–434. doi: 10.1007/s40263-013-0062-1Haddjeri N., Blier P., de Montigny C. Long-term antidepressant treat- ments result in a tonic activation of forebrain 5-HT1A receptors. J. Neurosci. 1998;18:10150–10156.Haddjeri N., Blier P., de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J. Neurosci. 1998;18:10150–10156.Schwartz T.L., Meszaros Z.S., Khan R., Nihalani N. How to control weight gain when prescribing antidepressants. Current Psychiatry. 2007;6(5):53–56.Schwartz T.L., Meszaros Z.S., Khan R., Nihalani N. How to control weight gain when prescribing antidepressants. Current Psychiatry. 2007;6(5):53–56.Lattimore K.A., Donn S.M., Kaciroti N., Kemper A.R., Neal C.J., Vazquez D.M. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J. Perinatol. 2005;25:595–604. doi: 10.1038/sj.jp.7211352Lattimore K.A., Donn S.M., Kaciroti N., Kemper A.R., Neal C.J., Vazquez D.M. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J. Perinatol. 2005;25:595–604. doi: 10.1038/sj.jp.7211352Gadot Y., Koren G. The use of antidepressants in pregnancy: Focus on maternal risks. J. Obstet. Gynaecol. Can. 2015;37(1):56–63.Gadot Y., Koren G. The use of antidepressants in pregnancy: Focus on maternal risks. J. Obstet. Gynaecol. Can. 2015;37(1):56–63.Palmsten K., Hernández-Díaz S., Huybrechts K.F., Williams P.L., Michels K.B., Achtyes E.D. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ. 2013;347:f4877. doi: https://doi.org/10.1136/ bmj.f4877Palmsten K., Hernández-Díaz S., Huybrechts K.F., Williams P.L., Michels K.B., Achtyes E.D. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ. 2013;347:f4877. doi: https://doi.org/10.1136/ bmj.f4877Boukhris T., Sheehy O., Mottron L., Bérard A. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr. 2016;170(2):117–124. doi: 10.1001/jamapediatrics.2015.3356Boukhris T., Sheehy O., Mottron L., Bérard A. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr. 2016;170(2):117–124. doi: 10.1001/jamapediatrics.2015.3356Nezvalová-Henriksen K., Spigset O., Brandlistuen R.E., Ystrom E., Koren G., Nordeng H. Effect of prenatal selective serotonin reuptake inhibitor (SSRI) exposure on birthweight and gestational age: a sibling-controlled cohort study. In. J. Epidemiol. 2016;(5):2018–2029. doi: 10.1093/ije/dyw049Nezvalová-Henriksen K., Spigset O., Brandlistuen R.E., Ystrom E., Koren G., Nordeng H. Effect of prenatal selective serotonin reuptake inhibitor (SSRI) exposure on birthweight and gestational age: a sibling-controlled cohort study. In. J. Epidemiol. 2016;(5):2018–2029. doi: 10.1093/ije/dyw049Brown A.S., Gyllenberg D., Malm H., McKeague I.W., Hinkka-Yli-Salomäki S., Artama M., Gissler M., Cheslack-Postava K., Weissman M.M., Gingrich J.A., Sourander A. Association of selective serotonin reuptake inhibitor exposure during pregnancy with speech, scholastic, and motor disorders in Offspring. JAMA Psychi- atry. 2016;73(11):1163–1170. doi: 10.1001/jamapsychiatry.2016.2594Brown A.S., Gyllenberg D., Malm H., McKeague I.W., Hinkka-Yli-Salomäki S., Artama M., Gissler M., Cheslack-Postava K., Weissman M.M., Gingrich J.A., Sourander A. Association of selective serotonin reuptake inhibitor exposure during pregnancy with speech, scholastic, and motor disorders in Offspring. JAMA Psychiatry. 2016;73(11):1163–1170. doi: 10.1001/jamapsychiatry.2016.2594Clements C.C., Castro V.M., Blumenthal S.R., Rosenfield H.R., Murphy S.N., Fava M., Erb J.L., Churchill S.E., Kaimal A.J., Doyle A.E., Robinson E.B., Smoller J.W., Kohane I.S., Perlis R.H. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Molecular Psychiatry. 2015;20:727–734. doi: 10.1038/ mp.2014.90Clements C.C., Castro V.M., Blumenthal S.R., Rosenfield H.R., Murphy S.N., Fava M., Erb J.L., Churchill S.E., Kaimal A.J., Doyle A.E., Robinson E.B., Smoller J.W., Kohane I.S., Perlis R.H. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Molecular Psychiatry. 2015;20:727–734.Shonkoff J.P., Boyce W.T., McEwen B.S. Neuroscience, molecular biology, and the childhood roots of health disparities: building a new framework for health promotion and disease prevention. JAMA. 2009;30(21):2252–2259.Shonkoff J.P., Boyce W.T., McEwen B.S. Neuroscience, molecular biology, and the childhood roots of health disparities: building a new framework for health promotion and disease prevention. JAMA. 2009;30(21):2252–2259.Schatzberg A., Haddad P., Kaplan E., Lejoyeux M., Rosenbaum J., Young, A. et al. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. Journal of Clinical Psychiatry. 1997;58(7):5–10.Schatzberg A., Haddad P., Kaplan E., Lejoyeux M., Rosenbaum J., Young, A. et al. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. Journal of Clinical Psychiatry. 1997;58(7):5–10.Levi-Montalcini R., Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J. Exp. Zool. 1951;116(2):321–361.Levi-Montalcini R., Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J. Exp. Zool. 1951;116(2):321–361.Barde Y.A., Edgar D., Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982;1(5):549–553.Barde Y.A., Edgar D., Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982;1,5:549–553.Timmusk T., Palm K., Metsis M., Reintam T., Paalme V., Saarma M., Persson H. Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron. 1993;Mar;10(3):475–489.Timmusk T., Palm K., Metsis M., Reintam T., Paalme V., Saarma M., Persson H. Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron. 1993;Mar;10(3):475–489.Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors. Author manuscript; available in PMC 2008 Aug 9. Published in final edited form as. Growth Factors. 2004;22(3):123– 131. doi: 10.1080/08977190410001723308Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors. Author manuscript; available in PMC 2008 Aug 9. Published in final edited form as. Growth Factors. 2004;22(3):123– 131. doi: 10.1080/08977190410001723308Leal G., Afonso P.M., Salazar I.L., Duarte C.B. Regulation of hippocampal synaptic plasticity by BDNF. Brain Res. 2015;1621:82–101. doi: 10.1016/j.brainres.2014.10.019Leal G., Afonso P.M., Salazar I.L., Duarte C.B. Regulation of hippocampal synaptic plasticity by BDNF. Brain Res. 2015;1621:82–101. doi: 10.1016/j.brainres.2014.10.019Lee B.H., Kim Y.K. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig. 2010;7(4):231–235. doi: 10.4306/pi.2010.7.4.231Lee B.H., Kim Y.K. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig. 2010;7(4):231–235. doi: 10.4306/pi.2010.7.4.231Björkholm C., Monteggia L.M. BDNF — a key transducer of antidepressant effects. Neuropharmacology. 2016;102(3):72–79. doi: 10.1016/j.neuropharm.2015.10.034Björkholm C., Monteggia L.M. BDNF — a key transducer of antidepressant effects. Neuropharmacology. 2016;102(3):72–79. doi: 10.1016/j.neuropharm.2015.10.034Martinowich K., Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology. 2008;33(1):73–83. doi: 10.1038/sj.npp.1301571Martinowich K., Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology. 2008;33(1):73–83. doi: 10.1038/sj.npp.1301571Yu H., Chen Z.Y. The role of BDNF in depression on the basis of its location in the neural circuitry. Acta Pharmacol. Sin. 2011;32(1):3–11. doi: 10.1038/aps.2010.184. Epub 2010 Dec 6Yu H., Chen Z.Y. The role of BDNF in depression on the basis of its location in the neural circuitry. Acta Pharmacol. Sin. 2011;32(1):3–11. doi: 10.1038/aps.2010.184. Epub 2010 Dec 6Bonne O., Gill J.M., Luckenbaugh D.A., Collins C., Owens M.J., Alesci S., Neumeister A., Yuan P., Kinkead B., Manji H.K., Charney D.S., Vythilingam M. Corticotropin-Releasing Factor, Interleukin-6, Brain-Derived Neurotrophic Factor, Insulin-Like Growth Factor-1, and Substance P in the cerebrospinal fluid of civilians with posttrau- matic stress disorder before and after treatment with paroxetine. J. Clin. Psychiatry. 2011;72(8):1124–1128. doi: 10.4088/JCP.09m05106bluBonne O., Gill J.M., Luckenbaugh D.A., Collins C., Owens M.J., Alesci S., Neumeister A., Yuan P., Kinkead B., Manji H.K., Charney D.S., Vythilingam M. Corticotropin-Releasing Factor, Interleukin-6, Brain-Derived Neurotrophic Factor, Insulin-Like Growth Factor-1, and Substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. J. Clin. Psychiatry. 2011;72(8):1124–1128. doi: 10.4088/JCP.09m05106bluCunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 2006;398:215–219. doi: 10.1016/j.neulet.2005.12.085Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 2006;398:215–219. doi: 10.1016/j.neulet.2005.12.085Palomino A., Vallejo-Illarramendi A., Gonzalez-Pinto A., Aldama A., Gonzalez-Gomez C., Mosquera F. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr. Res. 2006;86:321–322. doi: 10.1016/j.schres.2006.05.028Palomino A., Vallejo-Illarramendi A., Gonzalez-Pinto A., Aldama A., Gonzalez-Gomez C., Mosquera F. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr. Res. 2006;86:321–322. doi: 10.1016/j.schres.2006.05.028Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Ku- makiri C., Nakazato M., Watanabe H., Shinoda N., Okada S., Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry. 2003;54(1):70–75. doi: 10.1016/S0006-3223(03)00181-1Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., Nakazato M., Watanabe H., Shinoda N., Okada S., Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry. 2003;54(1):70–75. doi: 10.1016/S0006-3223(03)00181-1Lamego M.K., de Souza Moura A.M., Paes F., Ferreira Rocha N.B., de Sá Filho A.S., Lattari E., Rimes R., Manochio J., Budde H., Wegner M., Mura G., Arias-Carrión O., Yuan T.F., Nardi A.E., Machado S. Aerobic exercise does not predict brain derived neurotrophic factor and cortisol alterations in depressed patients. CNS Neurol. Disord. Drug Targets. 2015;14(9):1116–1128. doi: 10.2174/187152731566615 1111125402.Lamego M.K., de Souza Moura A.M., Paes F., Ferreira Rocha N.B., de Sá Filho A.S., Lattari E., Rimes R., Manochio J., Budde H., Wegner M., Mura G., Arias-Carrión O., Yuan T.F., Nardi A.E., Machado S. Aerobic exercise does not predict brain derived neurotrophic factor and cortisol alterations in depressed patients. CNS Neurol. Disord. Drug Targets. 2015;14(9):1116–1128. doi: 10.2174/1871527315666151111125402Rethorst C.D., Greer T.L., Toups M.S., Bernstein I., Carmody T.J., Trivedi M.H. IL-1β and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder. Transl. Psychiatry. 2015;5:e611. doi: 10.1038/tp.2015.104Rethorst C.D., Greer T.L., Toups M.S., Bernstein I., Carmody T.J., Trivedi M.H. IL-1β and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depres- sive disorder. Transl. Psychiatry. 2015;5:e611. doi: 10.1038/tp.2015.104Giese M., Unternährer E., Hüttig H., Beck J., Brand S., Calabrese P., Holsboer-Trachsler E., Eckert A. BDNF: An indicator of insomnia? Mol. Psychiatry. 2014;19(2):151–152. doi: 10.1038/mp.2013.10Giese M., Unternährer E., Hüttig H., Beck J., Brand S., Calabrese P., Holsboer-Trachsler E., Eckert A. BDNF: An indicator of insomnia? Mol. Psychiatry. 2014;19(2):151–152. doi: 10.1038/mp.2013.10Martinotti G., Pettorruso M., De Berardis D., Varasano P.A., Lucidi Pressanti G., De Remigis V., Valchera A., Ricci V., Di Nicola M., Janiri L., Biggio G., Di Giannantonio M. Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms. Int. J. Neuropsychopharmacol. 2016;19(5):1093. pyw003. doi: 10.1093/ijnp/pyw003.Martinotti G., Pettorruso M., De Berardis D., Varasano P.A., Lucidi Pressanti G., De Remigis V., Valchera A., Ricci V., Di Nicola M., Janiri L., Biggio G., Di Giannantonio M. Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms. Int. J. Neuropsychopharmacol. 2016;19(5):1093. pyw003. doi: 10.1093/ijnp/pyw003.

The authors declare that there are no conflicts of interest present.